Arno Therapeutics, Inc. HomeAbout UsPipelineInvestor RelationsContact Us
Arno Therapeutics is a biopharmaceutical company focused on the clinical development of targeted cancer therapies and novel drug candidates for unmet medical needs
Arno Theraoeutics, Inc.
Recent Press Releases In the news Contact

November 16, 2015
Arno Therapeutics Reports Third Quarter 2015 Financial Results and Business Update more »

October 29, 2015
Arno Therapeutics Data Demonstrate AR-12 as Novel Antifungal Drug Against Common Finger and Toenail Fungus, Onychomycosis more »

October 21, 2015
Arno Therapeutics Demonstrates AR-12 Has Potent Antiviral Activity Against Drug-Resistant HIV Strains more »

September 25, 2015
Arno Therapeutics to Present Late-Breaking Abstract on AR-12 as Novel Therapeutic Candidate Against HIV Multidrug Resistant Strains at 15th European AIDS Conference more »

September 24, 2015
Arno Therapeutics' AR-13 Data Show Promise as Potential New Therapeutic Option for Cystic Fibrosis Patients with Serious Bacterial Infections more »

September 19, 2015
Arno Therapeutics Data Demonstrates Novel Antimicrobial Activity of AR-12, Identified it as Lead Compound of New Class of Drugs more »

September 19, 2015
Arno Therapeutics to Present Data on Trans-Fungal Delivery of AR-12 at 2015 American Association of Pharmaceutical Scientists (AAPS) Annual Exposition more »

September 14, 2015
AR-12 Abstracts Accepted for Podium Presentation and Three Posters at ICAAC/ICC Annual Meeting 2015 more »

September 1, 2015
Arno Therapeutics to Present at 17th Annual Rodman & Renshaw Conference more »

View all Press Releases

July 16, 2015
ASCO 2015: Efficacy of Onapristone in PR-Expressing Tumors, Alexander Zukiwski, MD watch video »

July 16, 2015
ASCO 2015: Safety and PK Results From an Ongoing Phase I-II Study of ONA in Patients With PR-Expressing Cancers, Paul Cottu, MD, MSc watch video »

July 16, 2015
Arno explores new class of antimicrobial drugs more »

July 7, 2015
ASCO 2015: New data support continued onapristone and CDx development more »

April 8, 2015
Arno Therapeutics Seeks to Inhibit Cancer and Enhance Portfolios: CEO Alexander Zukiwski more »

May 23, 2014
Express Yourself: Arno, University of Minnesota pursue gene expression in hopes of developing a companion diagnostic more »

May 19, 2014
Do the Math: Ram Selvaraju on the Appeal of Biotechs in Orphan Diseases more »

May 9, 2014
Maxim: ARNI - Clinical progress on track; Onapristone in two dose escalation trials; Reiterating Buy and $6 price target more »

January 22, 2014
Maxim: ARNI - Onapristone now in clinical development; Revising estimates; Reiterating Buy and $6 price target more »

July 15, 2013
Orphan-Drug Marketing - Medical Marketing & Media (MM&M) eBook more »

July 8, 2013
APRs in CTCs - Drug Discovery News more »

June 13, 2013
Arno Therapeutics’ strategy is to develop onapristone companion diagnostics for each indication - Biopharm Insight more »

View All News

Arno Therapeutics, Inc.
200 Route 31 North
Suite 104
Flemington, NJ 08822

(862) 703-7170 Main
(908) 237-0071 Fax